Characteristic | Total | Osimertinib group | Osimertinib + RT group | χ2 | p | ||
---|---|---|---|---|---|---|---|
No | % | No | % | ||||
Gender | |||||||
 Male | 31 | 23 | 57.5 | 8 | 38.1 |  |  |
 Female | 30 | 17 | 42.5 | 13 | 61.9 | 2.075 | 0.150 |
Age (years) | |||||||
 Range | 33–74 | 37–74 |  | 33–65 |  |  |  |
 Median | 54 | 51.5 |  | 55 |  |  |  |
 < 65 | 52 | 32 | 80.0 | 20 | 95.2 |  |  |
 ≥ 65 | 9 | 8 | 20.0 | 1 | 4.8 | 2.542 | 0.146 |
Smoking status | |||||||
  Smoker | 13 | 7 | 17.5 | 6 | 28.6 |  |  |
 Never smoked | 48 | 33 | 82.5 | 15 | 71.4 | 1.007 | 0.341 |
Extracranial lesions | |||||||
 Yes | 56 | 37 | 92.5 | 19 | 90.5 |  |  |
 No | 5 | 3 | 7.5 | 2 | 9.5 | 0.075 | 1.000 |
Brain metastases | |||||||
 Symptomatic | 33 | 21 | 52.5 | 12 | 57.1 |  |  |
 Asymptomatic | 28 | 19 | 47.5 | 9 | 42.9 | 0.120 | 0.730 |
Number of brain metastases | |||||||
 ≤ 3 | 23 | 15 | 37.5 | 8 | 38.1 |  |  |
 > 3 | 38 | 25 | 62.5 | 13 | 61.9 | 0.002 | 0.964 |
Leptomeningeal metastases | |||||||
 Yes | 27 | 20 | 50.0 | 7 | 33.3 |  |  |
 No | 34 | 20 | 50.0 | 14 | 66.7 | 1.550 | 0.213 |
EGFR mutation | |||||||
 Exon 19 deletion | 30 | 20 | 50.0 | 10 | 47.6 |  |  |
 21 L858R | 31 | 20 | 50.0 | 11 | 52.4 | 0.031 | 0.860 |
T790M mutation | |||||||
 Positive | 51 | 33 | 82.5 | 18 | 85.7 |  |  |
 Unknown | 10 | 7 | 17.5 | 3 | 14.3 | 0.104 | 1.000 |
 Range | 0–5 | 0–4 |  | 0–5 |  |  |  |
 Median | 1 | 1 |  | 1 |  |  |  |
 0 | 7 | 4 | 10.0 | 3 | 14.3 |  |  |
 1 | 34 | 23 | 57.5 | 11 | 52.4 |  |  |
 > 1 | 20 | 13 | 32.5 | 7 | 33.3 | 0.449 | 0.927 |
Prior lines of TKI therapy | |||||||
 Range | 0–2 | 0–2 |  | 0–1 |  |  |  |
 Median | 1 | 1 |  | 1 |  |  |  |
 0 | 8 | 4 | 10.0 | 4 | 19.0 |  |  |
 1 | 52 | 35 | 87.5 | 17 | 81.0 |  |  |
 2 | 1 | 1 | 2.5 | 0 | 0 | 1.521 | 0.628 |